Erythrocytosis associated with a novel missense mutation in the BPGM gene

Nayia Petousi, Richard R. Copley, Terence R.j. Lappin, S.e. Haggan, Celeste Bento, Holger Cario, Melanie J. Percy, Peter J. Ratcliffe, Peter A. Robbins, M. F. McMullin, Peter Donnelly, John I. Bell, D. R. Bentley, Gil McVean, Jenny C. Taylor, Andrew O.m. Wilkie, P. Donelly, John Broxholme, David Buck, Jean‐Baptiste Cazier, Richard J. Cornall, Lynn Gregory, Julian C. Knight, Gerton Lunter, Ian Tomlinson, Christopher Allan, Moustafa Attar, Andrew Green, Sean Humphray, Zoya Kingsbury, Sarah Lamble, Lorne Lonie, Alistair T. Pagnamenta, Paolo Piazza, Guadelupe Polanco, Amy Trebes, Simon Fiddy, Russell Grocock, Edouard Hatton, Chris Holmes, L. Hughes, Peter Humburg, Alexander Kanapin, Stefano Lise, Hilary C. Martin, Lisa Murray, Davis J. McCarthy, Andy Rimmer, Natasha Sahgal, Bruce Wright, Christopher YauHaematologica 2014 · DOI · OpenAlex

Abstract

Erythrocytosis is characterized by an abnormally high concentration of red blood cells, often resulting from bone marrow disorders or defects in oxygen-sensing pathways. However, many cases remain "idiopathic" after standard clinical screening. We report the identification of a novel heterozygous missense mutation (c.269G>A; p.Arg90His) in the BPGM gene in a 27-year-old male with unexplained erythrocytosis. Bisphosphoglycerate mutase (BPGM) is responsible for the synthesis of 2,3-bisphosphoglycerate (2,3-BPG), a key regulator of hemoglobin-oxygen affinity. Our findings demonstrate that the R90H mutation reduces BPGM enzymatic activity and 2,3-BPG levels, leading to increased oxygen affinity and a compensatory overproduction of erythropoietin and red blood cells.

Introduction

Erythrocytosis presents a significant diagnostic challenge. While primary causes like Polycythemia Vera (often driven by JAK2 mutations) and secondary causes like chronic hypoxia or VHL mutations are well-documented, a subset of patients presents with high hemoglobin and hematocrit levels of unknown origin. In this study, we investigated a 27-year-old male with a hemoglobin level of 193 g/L. Despite five years of clinical investigation, standard tests for common genetic drivers were negative. This case highlights the utility of whole-genome sequencing (WGS) in uncovering rare genetic variants in metabolic pathways that influence oxygen delivery.

Methods

As part of the WGS500 Project, we performed whole-genome sequencing on the patient using the Illumina HiSeq2000 platform. Bioinformatics analysis utilized STAMPY for mapping and Platypus for variant calling, with a specific focus on genes involved in red blood cell regulation. To validate the findings, we performed Sanger sequencing on the patient and his parents. We also conducted biochemical assays to measure BPGM enzyme activity and 2,3-BPG concentrations in red blood cells. Finally, structural modeling was performed using PyMOL and the known crystal structure of human BPGM (PDB: 2HHJ) to assess the impact of the identified mutation on protein stability.

Results and Genetic Discovery

Whole-genome sequencing identified a novel heterozygous missense mutation in the BPGM gene (c.269G>A), resulting in an Arginine-to-Histidine substitution at residue 90 (p.Arg90His). Sanger sequencing confirmed that the patient inherited this mutation from his mother, while his father carried the wild-type allele.

Sanger sequencing chromatograms showing the heterozygous G>A mutation (indicated by the arrow) in the patient and his mother, confirming the inheritance pattern.

Clinical phenotyping revealed a significant "leftward shift" in the oxygen dissociation curve, with a $P_{50}$ of 23.91 mmHg (normal range: 27–33 mmHg). Biochemical analysis showed that the patient’s BPGM activity was reduced to 3.62 IU/g Hb (Control: 4.99) and 2,3-BPG levels were nearly halved at 14.5 µmol/g Hb (Control: 27.6). Interestingly, while the mother carried the same mutation and showed reduced 2,3-BPG levels, she did not exhibit clinical erythrocytosis, suggesting variable penetrance.

Molecular Mechanism

2,3-BPG is essential for stabilizing the deoxygenated (T-state) form of hemoglobin, which facilitates oxygen release to tissues. The R90 residue in BPGM is located near the active site and is critical for stabilizing the protein's structure through a network of hydrogen bonds.

Structural model of the BPGM active site showing the R90H mutation and its proximity to 2,3-BPG. The substitution disrupts stabilizing interactions, likely leading to reduced enzymatic efficiency.

Modeling suggests that replacing the positively charged Arginine with Histidine disrupts these stabilizing bonds (e.g., with W115 and E156), destabilizing the active site pocket. This structural impairment explains the observed reduction in BPGM activity and the subsequent drop in 2,3-BPG levels. The resulting high oxygen affinity of hemoglobin leads to relative tissue hypoxia, triggering the kidneys to produce more erythropoietin (15.9 mIU/mL in the patient) and stimulating red blood cell production.

Conclusion

This study identifies a novel BPGM mutation as a cause of hereditary erythrocytosis. It underscores the importance of considering 2,3-BPG deficiency in the differential diagnosis of idiopathic erythrocytosis, especially when patients exhibit a high-affinity oxygen dissociation curve. We recommend that BPGM be included in genetic screening panels for unexplained erythrocytosis to improve diagnostic accuracy and patient management.

Summary updated

Abstract

The ERYTHROPOIETIN (EPO) gene is regulated by the transcription factor Hypoxia Inducible Factor-alpha (HIF-alpha). In this pathway, Prolyl Hydroxylase Domain protein 2 (PHD2) hydroxylates two prolyl residues in HIF-alpha, which in turn promotes HIF-alpha degradation by the von Hippel Lindau (VHL) protein. Evidence that HIF-2alpha is the important isoform for EPO regulation in humans comes from the recent observation that mutations in the HIF2A gene are associated with cases of erythrocytosis. We report here a new erythrocytosis-associated mutation, p.Asp539Glu, in the HIF2A gene. Similar to all reported cases, the affected residue is in close vicinity and C-terminal to the primary hydroxylation site in HIF-2alpha, Pro531. This mutation, however, is notable in producing a rather subtle amino acid substitution. Nonetheless, we find that this mutation compromises binding of HIF-2alpha to both PHD2 and VHL, and we propose that this mutation is the cause of erythrocytosis in this individual.
BibTeX
@inproceedings{petousi2014erythrocytosis,
  author = {Nayia Petousi and Richard R. Copley and Terence R.J. Lappin and S.E. Haggan and Celeste Bento and Holger Cario and Melanie J. Percy and Peter J. Ratcliffe and Peter A. Robbins and M. F. McMullin and Peter Donnelly and John I. Bell and D. R. Bentley and Gil McVean and Peter J. Ratcliffe and Jenny C. Taylor and Andrew O.M. Wilkie and P. Donelly and John Broxholme and David Buck and Jean‐Baptiste Cazier and Richard J. Cornall and Lynn Gregory and Julian C. Knight and Gerton Lunter and Gil McVean and Ian Tomlinson and Andrew O.M. Wilkie and David Buck and Christopher Allan and Moustafa Attar and Andrew Green and Lynn Gregory and Sean Humphray and Zoya Kingsbury and Sarah Lamble and Lorne Lonie and Alistair T. Pagnamenta and Paolo Piazza and Guadelupe Polanco and Amy Trebes and Gil McVean and Peter Donnelly and Jean‐Baptiste Cazier and John Broxholme and Richard R. Copley and Simon Fiddy and Russell Grocock and Edouard Hatton and Chris Holmes and L. Hughes and Peter Humburg and Alexander Kanapin and Stefano Lise and Gerton Lunter and Hilary C. Martin and Lisa Murray and Davis J. McCarthy and Andy Rimmer and Natasha Sahgal and Bruce Wright and Christopher Yau},
  title = {{Erythrocytosis associated with a novel missense mutation in the BPGM gene}},
  booktitle = {Haematologica},
  year = {2014},
  doi = {10.3324/haematol.2014.109306},
}

Loading related content...

Figure